Because we show here that high levels of LRP2 are not only observed in clear cell renal cell carcinoma, but also in papillary renal cell carcinoma, mesothelioma, and in invasive breast carcinomas, we speculate that LRP2-targeted drug delivery might be effective in some of these cancer types as well. This evidence concerns the gene LRP2 and papillary renal cell carcinoma.